Entero Therapeutics, Inc. (NASDAQ:ENTO) Short Interest Down 55.3% in November

Entero Therapeutics, Inc. (NASDAQ:ENTO) saw a significant drop in short interest in November. As of November 30th, there was short interest totalling 68,300 shares, a drop of 55.3% from the November 15th total of 152,900 shares. Approximately 1.5% of the shares of the stock are short sold. Based on an average daily trading volume, of 471,000 shares, the days-to-cover ratio is presently 0.1 days.

Entero Therapeutics Trading Down 6.8 %

ENTO traded down $0.04 during midday trading on Friday, hitting $0.58. The company had a trading volume of 72,549 shares, compared to its average volume of 364,733. Entero Therapeutics has a twelve month low of $0.19 and a twelve month high of $14.51. The firm’s 50-day simple moving average is $0.57 and its 200-day simple moving average is $0.86.

Entero Therapeutics (NASDAQ:ENTO) last issued its quarterly earnings results on Monday, October 21st. The company reported ($3.37) earnings per share for the quarter. As a group, equities analysts anticipate that Entero Therapeutics will post -1.13 earnings per share for the current fiscal year.

About Entero Therapeutics

Entero Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the development of targeted and orally delivered therapies for the treatment of patients with gastrointestinal diseases. The company's pipeline candidates include latiglutenase, a targeted oral biotherapeutic for celiac disease designed to breakdown gluten into non-immunogenic peptides, currently under Phase 2 studies; and capeserod, a selective 5-HT4 receptor partial agonist under Phase 1 studies for the treatment of gastroparesis.